Cost Effectiveness of Oseltamivir Treatment for Patients with Influenza-Like Illness Who Are at Increased Risk for Serious Complications of Influenza: Illustration for The Netherlands

Author： Postma Maarten J.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.6, 2007-01, pp. : 497-509

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Influenza-like illness a burden in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 570, 2009-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Influenza-like illness (ILI) generates substantial costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 327, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients

By Griffin A.D.  

PharmacoEconomics, Vol. 19, Iss. 3, 2001-03 ,pp. : 293-301

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Zanamivir for the Treatment of Influenza in a High Risk Population in Australia

By Mauskopf J.A.  

PharmacoEconomics, Vol. 17, Iss. 6, 2000-06 ,pp. : 611-620

Adis International

Access to resources Recommend Favorite

Oseltamivir for treatment and prophylaxis of influenza infection

By Schirmer Patricia   Holodniy Mark  

Expert Opinion on Drug Safety, Vol. 8, Iss. 3, 2009-05 ,pp. : 357-371

Informa Healthcare

Access to resources Recommend Favorite